EQT and Goldman Sachs Asset Management completed the acquisition of Parexel from Pamplona for $8.5bn.

EQT and Goldman Sachs Asset Management, an asset management unit of GS, completed the acquisition of Parexel, a global clinical research organization focused on the development and delivery of innovative new therapies to advance patient, from Pamplona, a specialist investment manager, for $8.5bn. "Our investment in Parexel reflects EQT’s thematic focus on the life sciences industry, as well as our commitment to partner with businesses that have a positive impact on society. We are excited to partner with Goldman Sachs for the next stage of Parexel’s journey, and to back Jamie, who prior to his role at Parexel had been a long-time senior advisor to EQT, as well as the rest of the Parexel team," Eric Liu, EQT Partner and Global Co-Head of Healthcare.